Search Beyond News…

Willog's selection for Lloyd's Lab Cohort 17 makes it the first Korean insurtech to gain a foothold in the global insurance market through the prestigious Lloyd's accelerator

Executive summary: Willog was selected as one of ten companies for Lloyd's Lab Cohort 17, becoming the first Korean firm admitted to the program. The selection grants Willog entry to Lloyd's global insurance risk community and a platform to validate its solutions, potentially boosting its gross written premium and international reach.

Who is involved: Willog, Lloyd's Lab, and the participating Lloyd's insurance syndicates.

Likely next: Willog will undergo the Lloyd's Lab curriculum, with results such as pilot agreements or technology validations expected to be announced after the cohort ends.

Willog was chosen as one of ten companies from 280 worldwide applicants for Lloyd's Lab Cohort 17, and it is the sole Asian firm in the group. The program provides access to Lloyd's extensive insurance risk network and the chance to validate its technology, with alumni collectively generating over $400 million in gross written premium. This milestone positions Willog to expand its offerings internationally and could attract further investment or partnerships.

What's next — scenarios

Base: pilot secured after cohort (50%)

Willog completes Lloyd's Lab Cohort 17 and signs a pilot agreement with at least one Lloyd's syndicate within six months of program completion.

Upside: multi‑syndicate deployment (30%)

Willog secures commercial deployment agreements with two or more Lloyd's syndicates, generating over $10 million in gross written premium within twelve months.

Downside: no post‑cohort traction (20%)

Willog fails to secure any Lloyd's‑linked partnership after the cohort and refocuses on its domestic Korean market.

Timeline

Analysis — what this means

Sectors affected

Sources

Browse the full archive →